Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer – final appraisal consultation document

Source:
National Institute for Health and Care Excellence - NICE
Publisher:
National Institute for Health and Care Excellence
Publication date:
15 February 2019

Abstract

This DRAFT guidance recommends pertuzumab, with intravenous trastuzumab and chemotherapy for the adjuvant treatment of human epidermal growth factor receptor 2- positive early stage breast cancer in adults, only if they have lymph-node-positive disease.